DOI QR코드

DOI QR Code

Cisplatin Plus Gemcitabine for Treatment of Breast Cancer Patients with Brain Metastases: a Preferential Option for Triple Negative Patients?

  • Erten, Cigdem (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Demir, Lutfiye (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Somali, Isil (Department of Medical Oncology, Institute of Oncology, Faculty of Medicine, Dokuz Eylul University) ;
  • Alacacioglu, Ahmet (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Kucukzeybek, Yuksel (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Akyol, Murat (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Can, Alper (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Dirican, Ahmet (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Bayoglu, Vedat (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University) ;
  • Tarhan, Mustafa Oktay (Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University)
  • Published : 2013.06.30

Abstract

Background: To assess the efficacy and tolerability of Cisplatin plus Gemcitabine combination in patients with brain metastases (BM) from breast cancer (BC). Materials and Methods: Eighteen BC patients with BM who were treated with Cisplatin plus Gemcitabine regimen between 2003-2011 were evaluated. Results: A median of 6 cycles of this regimen were received, in fifteen patients (83.3%) as first-line chemotherapy, in 2 as second-line and in 1 as third-line after diagnosis of BM. Dose reduction was performed in 11 (61.1%) patients; major reasons were neutropenia and leukopenia. Grade III neutropenia and Grade II trombocytopenia rates were 33.3% and 16.7% respectively. Overall response rate (ORR; complete+partial response rate) was 33.4% (n=6) for the entire study population; triple negative patients achieved an 66.6% ORR while hormone receptor (HR) positive patients had 25% and HER2 positive patients 12.5%. Median progression-free survival was 5.6 months (2.4-8.8 months, 95%CI) and longer in patients with triple negative breast cancer (TNBC) (median 7.4 months, 95%CI, 2.4-12.3 months) than the patients with other subtypes (median 5 months for HER2 positive and 3.6 months for HR positive patients). Median PFS of the patients with TNBC who received this regimen as first-line was 9.2 months (5.2-13.2 months, 95%CI). Conclusions: Cisplatin plus Gemcitabine may be a treatment option for patients with BM from breast cancer. Longer PFS and higher response rates are results that support the usage of this regimen especially for the triple negative subtype. However, further prospective and randomized trials are clearly required to provide more exact information.

Keywords

Breast cancer;brain metastases;cisplatin plus gemcitabine;triple negative

References

  1. Bendell JC, Domchek SM, Burstein HJ, et al (2003). Central nervous system metastases in women receive trastuzumabbased therapy for metastatic breast carcinoma. Cancer, 97, 2972-7. https://doi.org/10.1002/cncr.11436
  2. Boogerd W (1996). Central nervous system metastasis in breast cancer. Radiother Oncol, 40, 5-22. https://doi.org/10.1016/0167-8140(96)01766-5
  3. Brodowicz T, Kostler WJ, Moslinger R, et al (2000). Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast, 9, 338-42. https://doi.org/10.1054/brst.2000.0170
  4. Byrski T, Huzarski T, Dent R, et al (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat, 115, 359-63. https://doi.org/10.1007/s10549-008-0128-9
  5. Cancer staging manual AJCC (2010) Seventh Edition, Springer, Chicago.
  6. Carey LA, Ewend MG, Metzger R, et al (2004). Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat, 88, 273-80. https://doi.org/10.1007/s10549-004-0999-3
  7. Carmichael J, Possinger K, Philip P, et al (1995). Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol, 13, 2731-6.
  8. DiStefano A, Yong YY, Hortobagyi GN, Blumenschein GR (1979). The natural history of breast cancer patients with brain metastases. Cancer, 44, 1913-8. https://doi.org/10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D
  9. Doroshow J, Tetef M, Margolin K, et al (2000). Significant activity of gemcitabine (Gem) and cisplatin (Ddp) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (Mbc) patients (Pts): a california cancer consortium/loyola Univ. Chicago Trial (Abstract). Proc Am Soc Clin Oncol, 19, 609.
  10. Eichler AF, Kuter I, Ryan P, et al (2008). Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer, 112, 2359-67. https://doi.org/10.1002/cncr.23468
  11. Elston CW, Ellis IO (1991). Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer:experience from a large study with long-term followup. Histopathology, 19, 403-10. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
  12. Forastiere AA, Hakes TB, Wittes JT, Wittes RE (1982). Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol, 5, 243-7. https://doi.org/10.1097/00000421-198206000-00001
  13. Fitzgibbons PL, Page DL, Weaver D, et al (2000). Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med, 124, 966-78.
  14. Gabos Z, Sinha R, Hanson J, et al (2006). Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol, 24, 5638-63.
  15. Ashworth A (2008). A synthetic lethal therapeutic approach: Poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol, 26, 3785-90. https://doi.org/10.1200/JCO.2008.16.0812
  16. Arslan UY, Oksuzoglu B, Aksoy S, et al (2011). Breast cancer subtypes and outcomes of central nervous system metastases. Breast, 20, 562-7. https://doi.org/10.1016/j.breast.2011.07.017
  17. Galvez CA, Calmarini F, Curie M (2000). Monthly cisplatin (C) and gemcitabine (G) as second line chemotherapy for patients with advanced breast cancer (Abstract). Breast Cancer Res Treat, 64, 81.
  18. Gorbunova VA, Bychkov MB, Naskhletashvili DR, et al (2010). Gemcitabine plus cisplatin in patients with heavily pretreated advanced breast cancer with brain metastases. J Clin Oncol, 28, 15. https://doi.org/10.1200/JCO.2008.20.9288
  19. Heinemann V (2002). Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer, 3, 24-9. https://doi.org/10.3816/CBC.2002.s.006
  20. Heinemann V, Stemmler HJ, Wohlrab A, et al (2006). High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol, 57, 640-6. https://doi.org/10.1007/s00280-005-0093-5
  21. Husain A, He G, Venkatraman ES, Spriggs DR (1998). BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res, 58, 1120-3.
  22. Kim H-J, Im S-A, Keam B, et al (2012). Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol, 106, 303-13. https://doi.org/10.1007/s11060-011-0664-8
  23. Kirsch DG, Ledezma CJ, Mathews CS, et al (2005). Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol, 23, 2114-6. https://doi.org/10.1200/JCO.2005.05.249
  24. Kolaric K, Roth A (1983). Phase II clinical trial of cisdichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol, 11, 108-12. https://doi.org/10.1007/BF00254257
  25. Lee SS, Ahn J-H, Kim MK, et al (2008). Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat, 111, 523-30. https://doi.org/10.1007/s10549-007-9806-2
  26. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW (2007). The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest, 117, 1370-80. https://doi.org/10.1172/JCI30866
  27. Maki DD, Grossman RI (2000). Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. Am J Neuroradiol, 21, 1064-6.
  28. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  29. Nam BH, Kim SY, Han HS, et al (2008). Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res, 10, 20.
  30. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000). Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol, 18, 2245-9.
  31. Niwinska A, Murawska M, Pogoda K (2010). Breast cancer brain metastasis: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT). Ann Oncol, 21, 942-8. https://doi.org/10.1093/annonc/mdp407
  32. Niwinska A, Murawska M, Pogoda K (2010). Breast cancer subtypes and response to systemic treatment after wholebrain radiotherapy in patients with brain metastases. Cancer, 116, 4238-47. https://doi.org/10.1002/cncr.25391
  33. Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol, 5, 649-55. https://doi.org/10.1097/00000421-198212000-00014
  34. Ostrow S, Egorin M, Aisner J, Bchur N, Wiernik PH (1980). High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials, 3, 23-7.
  35. Park B-B, Uhm JE, Cho EY, et al (2009). Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes? Cancer Chemother Pharmacol, 63, 627-33. https://doi.org/10.1007/s00280-008-0779-6
  36. Ryberg M, Nielsen D, Osterlind K, et al (2005). Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat, 91, 217-25. https://doi.org/10.1007/s10549-005-0323-x
  37. Samaan NA, Buzdar AU, Aldinger KA, et al (1981). Estrogen receptor: a prognostic factor in breast cancer. Cancer (Phila), 47, 554-60. https://doi.org/10.1002/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W
  38. Shen SX, Weaver Z, Xu X, et al (1998). A targeted disruption of the murine brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene, 17, 3115-24. https://doi.org/10.1038/sj.onc.1202243
  39. Sledge GW Jr. Loehrer PJ Sr. Roth BJ, Einhorn LH (1988). Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol, 6, 1811-4.
  40. Somali I, Alacacioglu A, Tarhan MO, et al (2009). Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy, 55, 155-60. https://doi.org/10.1159/000214143
  41. Spielmann M, Llombart- Cussac A, Kalla S, et al (2001). Singleagent gemcitabine is active in previously treated metastatic breast cancer. Oncology, 60, 303-7. https://doi.org/10.1159/000058524
  42. Tsukada Y, Fouad A, Pickren JW, Lane WW (1983). Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer (Phila), 52, 2349-54. https://doi.org/10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B
  43. Uhm JE, Park YH, Yi SY, et al (2009). Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer, 124, 1457-62. https://doi.org/10.1002/ijc.24090
  44. Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ (2012). Molecular insights on basal-like breast cancer. Breast Cancer Res Treat, 134, 21-30. https://doi.org/10.1007/s10549-011-1934-z
  45. Valerio M, Cicero G, Armata M, et al (2001). Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol, 20, 1953.
  46. World Health Organization: WHO handbook for reporting results of cancer treatment (1979) WHO Offset Publication, No. 48, Geneva, Switzerland.

Cited by

  1. Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients vol.17, pp.4, 2014, https://doi.org/10.4048/jbc.2014.17.4.339
  2. Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation vol.12, pp.4, 2015, https://doi.org/10.1021/mp5008629
  3. Brain Metastases from Solid Tumors: an Institutional Study from South India vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5401
  4. Protective Role of Selenium and High Dose Vitamin E against Cisplatin - Induced Nephrotoxicty in Rats vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6877
  5. Incidence of Cisplatin-Induced Nephrotoxicity and Associated Factors among Cancer Patients in Indonesia vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1117
  6. A New Tool to Predict Survival after Radiosurgery Alone for Newly Diagnosed Cerebral Metastases vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2967
  7. )-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549) vol.89, pp.3, 2016, https://doi.org/10.1111/cbdd.12845
  8. A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer vol.7, pp.4, 2017, https://doi.org/10.1051/bmdcn/2017070423
  9. Leptomeningeal Metastases vol.19, pp.1, 2018, https://doi.org/10.1007/s11864-018-0518-0
  10. Metastatic and triple-negative breast cancer: challenges and treatment options vol.8, pp.5, 2018, https://doi.org/10.1007/s13346-018-0551-3